Understanding sepsis in ICU patients using advanced data analysis
Personalized Swiss Sepsis Study: With Machine Learning and Computational Modelling Towards Personalized Sepsis Management - Discovery of Digital Biomarkers
This study looks at patients with sepsis in ICUs to see if advanced data analysis can help find new ways to diagnose the condition better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 17500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 16 sites (Basel and 15 other locations) |
| Trial ID | NCT04130789 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with sepsis in Intensive Care Units (ICUs) to explore the complex interactions between hosts and pathogens. By utilizing state-of-the-art analytical algorithms, including machine learning and multidimensional modeling, the study aims to analyze large datasets to identify digital biomarkers. A case-control design will compare data patterns from patients with sepsis to those without, potentially leading to novel diagnostic approaches for sepsis. The study is conducted across multiple centers in Switzerland, specifically within university hospitals.
Who should consider this trial
Good fit: Ideal candidates include ICU patients in Swiss university hospitals who are expected to stay for at least 24 hours and either present with or develop sepsis.
Not a fit: Patients who are admitted for elective stays in the ICU or decline consent for data use may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for sepsis, enhancing patient outcomes.
How similar studies have performed: Other studies utilizing machine learning for sepsis diagnosis have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients admitted to an ICU on a Swiss University Hospital. * Patients expected to stay at least 24h on the ICU Inclusion Criteria (cases) * Present at admission to ICU or subsequent development of sepsis 3.0 criteria Inclusion Criteria (controls) * Patients not fulfilling sepsis definition during the ICU stay Exclusion Criteria: * Decline of general consent or any other negative statement against using data for research. * Patients with a clear elective stay on the ICUs.
Where this trial is running
Basel and 15 other locations
- Clinical Microbiology, University Hospital Basel — Basel, Switzerland (Recruiting)
- Infectious Diseases and Hospital Epidemiology, University Hospital Basel — Basel, Switzerland (Recruiting)
- Medical Intensive Care Unit; University Hospital Basel — Basel, Switzerland (Recruiting)
- Surgical Intensive Care Unit, University Hospital Basel — Basel, Switzerland (Recruiting)
- Institute for Infectious Diseases, University of Bern — Bern, Switzerland (Recruiting)
- Division Infectious Diseases, University Hospital Bern — Bern, Switzerland (Recruiting)
- Intensive Care Medicine, University Hospital Bern — Bern, Switzerland (Recruiting)
- Division Bacteriology Laboratory, University Hospital Geneva — Geneva, Switzerland (Recruiting)
- Division Infectious Diseases, University Hospital Geneva — Geneva, Switzerland (Recruiting)
- Intensive Care Medicine, University Hospital Geneva — Geneva, Switzerland (Recruiting)
- Division Intensive Care Medicine, University Hospital Lausanne — Lausanne, Switzerland (Recruiting)
- Institute of Microbiology, University Hospital Lausanne — Lausanne, Switzerland (Recruiting)
- Service Infectious Diseases, University Hospital Lausanne — Lausanne, Switzerland (Recruiting)
- Institute for Medical Microbiology, University Hospital Zurich — Zurich, Switzerland (Not_yet_recruiting)
- Division Infectious Diseases, University Hospital Zurich — Zurich, Switzerland (Not_yet_recruiting)
- Institute for Intensive Medicine, University Hospital Zurich — Zurich, Switzerland (Not_yet_recruiting)
Study contacts
- Principal investigator: Adrian Egli, PD Dr. — Clinical Microbiology, University Hospital Basel
- Study coordinator: Adrian Egli, PD Dr.
- Email: adrian.egli@usb.ch
- Phone: +41 61 556 5749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.